Large group of adults and children posing and wearing sunglasses.

let's recode what's possible



  • our first approval!

    June 03, 2019

    The flock receives EU Conditional Marketing Authorization for our first product, ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene)

  • We Receive Positive CHMP Opinion

    March 29, 2019
  • A group of bluebird bio employees participating in a celebratory ribbon cutting ceremony in front of a building

    bRT Ribbon Cutting

    March 21, 2019

    Our nest in North Carolina is open for business!

  • Inhibrix's Company Logo

    We Announce A Partnership With Inhibrix

    January 07, 2019

    bluebird bio announces exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets.


  • Illustration of a heart and an infusion bag

    Our Regulatory Application Is Accepted By The EMA

    October 05, 2018

    bluebird bio announces European Medicines Agency’s Acceptance of Marketing Authorization Application of our investigational treatment for patients with transfusion-dependent β-thalassemia.

  • Gritstone's Company Logo

    We Announce Partnership With Gritstone Oncology, Inc.

    August 23, 2018

    bluebird bio announces a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

  • Regeneron's Company Logo

    Strategic Collaboration With Regeneron Announced

    August 06, 2018

    bluebird bio announces collaboration with Regeneron to discover, develop and commercialize new cell therapies for cancer

  • Picture of a mother and father seated on either side of their son with cerebral adrenoleukodystrophy

    FDA Grants Us Breakthrough Therapy Designation In ALD

    May 23, 2018

    bluebird's investigational gene therapy for cerebral ALD was granted Breakthrough Therapy designation by the U.S. FDA.

  • America’s Got Talent contestant, Mandy Harvey, in the bluebird bio offices with a plush bird stuffed animal on her head

    Our First Superstar Day

    May 20, 2018

    Each bird is allowed to invite 1-2 people that inspire them to visit the office and to see what we do here on behalf of patients. Our speaker and performer for year one was America’s Got Talent contestant, Mandy Harvey.


  • TCBiopharma's Company Logo

    Strategic Collaboration With TC Biopharma Announced

    December 07, 2017

    Collaboration with TC Biopharma announced to research and develop Gamma Delta CAR T cell product candidates for cancer immunotherapy

  • Whiteboard with handwritten welcome message and bird drawings

    We Move To The Newest Nest!

    March 21, 2017

    Our Facilities team celebrates after receiving the Certificate of Occupancy for our new nest at 60 Binney, Cambridge MA.


  • Apceth's Company Logo

    We Enter Into A Partnership With Apceth Biopharma

    December 15, 2016

    Our manufacturing relationship with Apceth provides us with European commercial manufacturing capabilities

  • Medigene's Company Logo

    R&D Collaboration With Medigene Announced

    September 29, 2016

    bluebird  bio announces strategic research and development collaboration and licensing agreement with Medigene AG for T cell receptor (TCR) immunotherapies against four targets.

  • Illustration of red blood cells

    We Receive PRIME Designation By The EMA

    September 21, 2016

    Our investigational treatment for patient with transfusion-dependent β-thalassemia was given PRIME designation by European Medicines Agency (EMA)

  • Lonza's Company Logo

    We Enter Into A Strategic Agreement With Lonza

    June 09, 2016

    bluebird bio announces strategic manufacturing agreement with Lonza Houston, Inc., providing for future commercial production of our drug products

  • bluebird bio's first European employee sitting in a chair holding a sign that says 'make your mark'

    Our First EU Bird Joins The Nest

    June 06, 2016

    Gabriella joined the nest as our first hire in Italy. We now have EU birds in Switzerland, Italy, France, the Netherlands, and the UK too!

  • Pediatric patient walking down the bluebird bio hallway high-fiving employees lined up on either side

    Daron's bluebird Day

    April 29, 2016

    bluebird invites Daron, a 12 year old boy fighting cancer, to be our Chief Scientific Officer for the day! All birds fly with Daron!

  • First Multiple Myeloma Patient Treated

    February 17, 2016

    First patient treated with bb2121 anti-BCMA CAR T cell therapy in Phase 1 study in patients with relapsed/refractory multiple myeloma.


  • First Sickle Cell Disease Patient Treated

    October 14, 2014

    The first patient treated in a clinical study of our investigational treatment for sickle cell disease was a milestone for bbb and patients.

  • First Transfusion-Dependent β-thalassemia Patient Treated

    May 03, 2014

    The first patient treated in a clinical study of our investigational treatment for β-thalassemia was a milestone for bbb and patients.


  • Exterior photograph of the building at 150 Second Street in Cambridge Massachusetts

    We Move to 150 Second Street in Cambridge

    December 29, 2013

    As bluebird continues to grow, the team moves to their new nest at 150 Second Street in Cambridge.

  • Members of the Ethan Zakes Foundation holding two of Ethan's skateboards

    First Ever bbb Auction!

    September 18, 2013

    The all-employee auction has become an annual bluebird tradition. Each year, employees donate and bid on items to raise money for the charity of our choosing including the Ethan Zakes Foundation, Brian’s Hope, Sickle Cell Community Consortium, Thalassemia Support Foundation and most recently in 2018 for Stupid Cancer.

  • Pregenen's Company Logo

    We Acquire Pregenen

    June 30, 2013

    bluebird expands to the West Coast by acquiring some kick-ass birds with a unique gene editing platform. We now have a nest in Seattle, WA.

  • Group photograph of all bluebird employees present on the day of the company's IPO

    $BLUE Goes Public

    June 19, 2013

    bluebird's initial public offering (IPO)

  • Celgene's Company Logo

    Collaboration with Celgene Announced

    March 15, 2013

    bluebird collaborates with Celgene to discover, develop and commercialize novel, disease-altering gene therapies in oncology.


  • Group photograph of bluebird bio employees participating in BioBall

    First Participation in BioBall

    April 28, 2012

    BioBall is a one day basketball tournament that partners with the Mass Bio-Tech community to raise money for Special Olympics Massachusetts. - BioBall is now an annual tradition for bluebird.


  • bluebird bio's CEO Nick Leschley pictured with Phil Reilly, bluebird bio's first Chief Medical Officer at the company's first ever offsite

    Founding Day of bluebird bio

    September 09, 2010

    Genetix becomes bluebird


  • Genetix's original company logo

    Genetix Founded

    April 16, 1992